Ab­b­Vie wins a 5-year free pass on mega-block­buster Hu­mi­ra in biosim set­tle­ment with ri­val Am­gen

It was clear from a re­cent sit-down with Leerink’s Ge­of­frey Porges that Ab­b­Vie was feel­ing good about keep­ing its mega-block­buster Hu­mi­ra fran­chise in the US to it­self through 2022. And this morn­ing we got a peek in­to why they were so bull­ish.

Am­gen, which scored the first ap­proval for a biosim­i­lar of Hu­mi­ra in the US, has signed off on a set­tle­ment agree­ment with Ab­b­Vie that will de­lay its roll­out un­til ear­ly 2023. Am­gen can get start­ed in the EU in the fall of next year, with a mar­ket­ing pact that calls on the com­pa­ny to pay roy­al­ties to Ab­b­Vie.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER